US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose by 6% as Semaglutide's market exclusivity in China is extended.
On Monday, Novo Nordisk (NVO.US) rose by 6% to $45.79.
On Monday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose 6% to $45.79. In terms of news, the CEO of Novo Nordisk A/S Sponsored ADR Class B recently announced that the regulatory data protection period for the company's flagship product Semaglutide in China will continue until April 2027, which is more than a year after the expiration of the core compound's patent in March 2026. It is estimated that this extended 13-month protection period could bring the company an additional stable cash flow of around $1 billion.
Related Articles
US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.
Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.
US Stock Market Move | SpaceX (SPCX.US) falls more than 9%, accumulating a 20% drop over three consecutive trading days.
US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.
Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.
US Stock Market Move | SpaceX (SPCX.US) falls more than 9%, accumulating a 20% drop over three consecutive trading days.
RECOMMEND
